米国の膵外分泌機能不全診断の市場規模、シェア、動向分析レポート：診断方法別、最終用途別、セグメント別予測、2024年-2030年

米国の膵外分泌機能不全診断市場の成長と動向

Grand View Research社の最新レポートによると、米国の膵外分泌機能不全診断の市場規模は2030年までに23億9,000万米ドルに達し、2024年から2030年までのCAGRは7.04％で成長すると予測されています。

膵臓疾患の罹患率の増加、技術の進歩、有利な政府のイニシアチブと資金提供など、いくつかの要因が市場成長を促進しています。業界の主要な将来動向は、機械学習アルゴリズムや人工知能（AI）と診断ツールの統合です。例えば、gastroenterology-AIプラットフォームのようなAIベースのソフトウェア・プラットフォームは、CTスキャンやMRIからの医療画像データを分析し、医療専門家が膵不全の兆候をより正確かつ効率的に特定できるよう支援します。このような技術動向は、将来的に診断精度を高め、解釈ミスを減らし、患者の転帰を改善すると予想され、予測期間中の製品需要を促進します。

市場の競争が激化する中、高収量・高信頼性の診断機器や消耗品の改良に対する消費者のニーズはかつてないほど高まっています。CTスキャンやMRIにおけるAIのような新時代の技術は、旧来の製品の販売を阻害し、市場に新たな研究開発の機会を開くと予想されます。価格、互換性、安全性、結果提供に要する時間は、新しいEPI検査技術を既存のEPI検査技術と差別化する主要要因であり、それによって競合優位性を獲得しています。例えば、ALPCO Diagnostics社は、便中の膵エラスターゼを迅速かつ正確に検出するために設計された、膵エラスターゼ（PE）化学発光ELISAおよびCLIA検査を含む最先端の検査法を発表しています。これらの高度なアッセイは、ヘルスケア専門家にEPIを診断する信頼性の高い手段を提供し、迅速な介入と患者の転帰の改善を促します。しかし、各社はより高い有効性を有し、より低コストで入手可能な新製品の開発に注力しています。

米国の膵外分泌機能不全診断市場レポート・ハイライト

• 診断方法に基づくと、2023年にはラボラトリー検査分野が最大の収益シェアを占めました。ラボ検査には、間接的な膵機能検査や、膵炎の遺伝子検査（遺伝性膵炎遺伝子パネルなど）、患者の外分泌膵不全を診断するための13C混合トリグリセリド呼気検査などのその他の検査が含まれます。
• 一方、血液検査や便検査を含む間接的な膵機能検査セグメントは、予測期間中に大きなCAGRで成長すると予想されます。
• 最終用途に基づくと、病院・診療所セグメントは2023年に最大の収益シェアを占めました。
• 全国に病院・診療所の強力なネットワークが存在し、重症EPIの診断に熟練したスタッフが利用できることが、診断と治療において病院・診療所が高く選ばれている主な要因の1つです。
• 市場の合併・買収の動きは低水準から中程度であり、安定した競争と外部からの統合よりも内部発展への集中を特徴とする情勢を示しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の膵外分泌機能不全診断市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場 促進要因分析
  • 市場抑制要因分析
• 米国の膵外分泌機能不全診断市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
• 規制シナリオ
• 払い戻しシナリオ
• 価格分析
• 対象人口分析

第4章 米国の膵外分泌機能不全診断市場：診断方法別推定・動向分析

• 米国の膵外分泌機能不全診断市場：診断方法セグメントダッシュボード
• 米国の膵外分泌機能不全診断市場：診断方法の変動分析
• 米国の膵外分泌機能不全診断市場規模と動向分析、診断方法別、2018～2030年
• 臨床検査
• 画像検査

第5章 米国の膵外分泌機能不全診断市場：最終用途別推定・動向分析

• 米国の膵外分泌機能不全診断市場：最終用途セグメントダッシュボード
• 米国の膵外分泌機能不全診断市場：最終用途変動分析
• 米国の膵外分泌機能不全診断市場規模と動向分析、最終用途別、2018～2030年
• 病院・クリニック
• 診断検査室
• 研究機関

第6章 競合情勢

• 参入企業の分類
• 参入企業概要
• 財務実績
• 製品ベンチマーク
• ヒートマップ分析
• ベンダー情勢
  • 主なディストリビューターとチャネルパートナーのリスト
  • 消費者行動分析
  • ChiRhoClin
  • Certest Biotec.
  • ScheBo Biotech AG
  • Immundiagnostik AG
  • Laboratory Corporation of America Holdings
  • Boster Biological Technology
  • ALPCO Diagnostics
  • Quest Diagnostics Incorporated
  • DiaSorin SpA
  • ARUP Laboratories
  • Alpha Laboratories
  • Verisana Laboratories

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviation
• Table 3 U.S. Exocrine Pancreatic Insufficiency Diagnostics market revenue estimates and forecast, by Diagnostic Method, 2018 - 2030 (USD Million)
• Table 4 U.S. exocrine pancreatic insufficiency diagnostics market revenue estimates and forecast, by end-use, 2018 - 2030 (USD Million)
• Table 5 Laboratory information U.S.
• Table 6 List of players adopting merger & acquisition strategy
• Table 7 List of players adopting acquisition strategy
• Table 8 List of players adopting other strategy

List of Figures

• Fig. 1 U.S. exocrine pancreatic insufficiency diagnostics market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 QFD modelling for market share assessment.
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Diagnostic method and end-use segment snapshot
• Fig. 10 Competitive landscape snapshot
• Fig. 11 Market dynamics
• Fig. 12 Porter's five forces analysis
• Fig. 13 PESTLE analysis
• Fig. 14 U.S. Exocrine Pancreatic Insufficiency Diagnostics market: Diagnostic Method outlook and key takeaways
• Fig. 15 U.S. Exocrine Pancreatic Insufficiency Diagnostics market: Diagnostic Method movement analysis
• Fig. 16 Laboratory Tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 17 Laboratory Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 18 Indirect Pancreatic Function Tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Indirect Pancreatic Function Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 20 Stool Tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Stool Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 22 Blood Tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Blood Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 24 Other tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Other tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 26 Imaging tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Imaging tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 28 CT scans market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 CT scans market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 30 MRI market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Endoscopic ultrasound for pancreatic function tests for pancreatic function tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Endoscopic ultrasound for pancreatic function tests for pancreatic function tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 33 U.S. exocrine pancreatic insufficiency diagnostics market: By end-use, key takeaways
• Fig. 34 U.S. exocrine pancreatic insufficiency diagnostics market, by end-use: Market share, 2023 & 2030
• Fig. 35 Hospitals and clinics market, 2018 - 2030 (USD Million)
• Fig. 36 Diagnostic laboratories market, 2018 - 2030 (USD Million)
• Fig. 37 Research institutes market, 2018 - 2030 (USD Million)
• Fig. 38 Research institutes market, 2018 - 2030 (Number of Tests, '000)
• Fig. 39 Company/competition categorization
• Fig. 40 Heat map analysis
• Fig. 41 Consumer behavior analysis
• Fig. 42 Exocrine pancreatic insufficiency diagnostics industry key takeaways
• Fig. 43 Strategy mapping

U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Growth & Trends:

The U.S. exocrine pancreatic insufficiency diagnostics market size is expected to reach USD 2.39 billion by 2030, growing at a CAGR of 7.04% from 2024 to 2030, according to a new report by Grand View Research, Inc. Several factors are driving market growth, including increasing incidence of pancreatic diseases, technological advancements, and favorable government initiatives & funding. A key future trend in the industry is the integration of machine learning algorithms and Artificial Intelligence (AI) with diagnostic tools. For instance, AI-based software platforms like the gastroenterology-AI platform analyze medical imaging data from CT scans or MRIs to assist healthcare professionals in identifying signs of pancreatic insufficiency more accurately and efficiently. This technological trend is expected to enhance diagnostic accuracy, reduce interpretation errors, and improve patient outcomes in the future, thereby driving the demand for products over the forecast period.

As the market becomes increasingly competitive, consumer needs are at an all-time high for improved diagnostic instruments and consumables in terms of high yield & robust outcomes. New-age technologies, such as AI in CT scans and MRIs, are expected to impede the sales of older products, opening new R&D opportunities in the market. Price, compatibility, safety, and time taken to provide results are major factors differentiating new EPI testing technologies from existing ones, thereby gaining a competitive edge over them. For instance, ALPCO Diagnostics introduces state-of-the-art assays, including the Pancreatic Elastase (PE) Chemiluminescence ELISA and CLIA tests, designed to detect pancreatic elastase rapidly & accurately in the stool. These advanced assays offer healthcare professionals a reliable means of diagnosing EPI, facilitating prompt intervention and improved patient outcomes. However, companies are focusing on developing newer products with higher efficacy made available at lower costs.

U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Report Highlights:

• Based on diagnostic method, the laboratory tests segment accounted for the largest revenue share in 2023. Laboratory tests include indirect pancreatic function tests and other tests such as genetic testing for pancreatitis (such as Hereditary Pancreatitis Gene Panel) and 13C-mixed triglyceride breath tests for diagnosing exocrine pancreatic insufficiency in patients.
• On the other hand, the indirect pancreatic function test segment, which includes blood tests and stool tests, is expected to grow at a significant CAGR during the forecast period.
• Based on end-use, the hospitals and clinics segment accounted for the largest revenue share in 2023.
• The presence of a strong network of hospitals & clinics throughout the country and the availability of skilled staff for diagnosing severe EPI are some of the key factors responsible for the high preference of hospitals & clinics for diagnosis and treatment.
• The market is characterized by a low-to-moderate level of merger and acquisition activity, indicating a landscape characterized by stable competition and a focus on internal development rather than external consolidation.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Diagnostic Method
  • 1.2.2. End-use
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Diagnostic Method Outlook
  • 2.2.2. End-use Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of target disease
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Growing awareness and screening initiatives
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory hurdles and compliance requirements
    • 3.2.2.2. Underdiagnosis and misdiagnosis
• 3.3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Regulatory Scenario
• 3.5. Reimbursement Scenario
• 3.6. Pricing Analysis
• 3.7. Target Population Analysis

Chapter 4. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Estimates & Trend Analysis

• 4.1. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Segment Dashboard
• 4.2. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Movement Analysis
• 4.3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Size & Trend Analysis, by Diagnostic Method, 2018 to 2030 (USD Million)
• 4.4. Laboratory Tests
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Indirect Pancreatic Function Tests
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. Stool Tests
    • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. Blood Tests
    • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Other Tests
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Imaging Tests
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. CT Scans
    • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. MRI
    • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Endoscopic Ultrasound for Pancreatic Function Tests
    • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Estimates & Trend Analysis

• 5.1. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Segment Dashboard
• 5.2. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Movement Analysis
• 5.3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 5.4. Hospitals & Clinics
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Diagnostic Laboratories
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Research Institutes
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Categorization
• 6.2. Participant Overview
• 6.3. Financial Performance
• 6.4. Product Benchmarking
• 6.5. Heat Map Analysis
• 6.6. Vendor Landscape
  • 6.6.1. List of key distributors and channel partners
  • 6.6.2. Consumer behavior analysis
  • 6.6.3. ChiRhoClin
    • 6.6.3.1. Company overview
    • 6.6.3.2. Financial performance
    • 6.6.3.3. Product benchmarking
    • 6.6.3.4. Strategic initiatives
  • 6.6.4. Certest Biotec.
    • 6.6.4.1. Company overview
    • 6.6.4.2. Financial performance
    • 6.6.4.3. Product benchmarking
    • 6.6.4.4. Strategic initiatives
  • 6.6.5. ScheBo Biotech AG
    • 6.6.5.1. Company overview
    • 6.6.5.2. Financial performance
    • 6.6.5.3. Product benchmarking
    • 6.6.5.4. Strategic initiatives
  • 6.6.6. Immundiagnostik AG
    • 6.6.6.1. Company overview
    • 6.6.6.2. Financial performance
    • 6.6.6.3. Product benchmarking
    • 6.6.6.4. Strategic initiatives
  • 6.6.7. Laboratory Corporation of America Holdings
    • 6.6.7.1. Company overview
    • 6.6.7.2. Financial performance
    • 6.6.7.3. Product benchmarking
    • 6.6.7.4. Strategic initiatives
  • 6.6.8. Boster Biological Technology
    • 6.6.8.1. Company overview
    • 6.6.8.2. Financial performance
    • 6.6.8.3. Product benchmarking
    • 6.6.8.4. Strategic initiatives
  • 6.6.9. ALPCO Diagnostics
    • 6.6.9.1. Company overview
    • 6.6.9.2. Financial performance
    • 6.6.9.3. Product benchmarking
    • 6.6.9.4. Strategic initiatives
  • 6.6.10. Quest Diagnostics Incorporated
    • 6.6.10.1. Company overview
    • 6.6.10.2. Financial performance
    • 6.6.10.3. Product benchmarking
    • 6.6.10.4. Strategic initiatives
  • 6.6.11. DiaSorin S.p.A.
    • 6.6.11.1. Company overview
    • 6.6.11.2. Financial performance
    • 6.6.11.3. Product benchmarking
    • 6.6.11.4. Strategic initiatives
  • 6.6.12. ARUP Laboratories
    • 6.6.12.1. Company overview
    • 6.6.12.2. Financial performance
    • 6.6.12.3. Product benchmarking
    • 6.6.12.4. Strategic initiatives
  • 6.6.13. Alpha Laboratories
    • 6.6.13.1. Company overview
    • 6.6.13.2. Financial performance
    • 6.6.13.3. Product benchmarking
    • 6.6.13.4. Strategic initiatives
  • 6.6.14. Verisana Laboratories
    • 6.6.14.1. Company overview
    • 6.6.14.2. Financial performance
    • 6.6.14.3. Product benchmarking
    • 6.6.14.4. Strategic initiatives